Founding Partner & Managing Director
James (Jim) Gale is the founding partner of Signet Healthcare Partners. Jim has over 30 years of healthcare investing and finance experience.
Jim is a Managing Director in Signet Fund IV and is currently the Chairman of the Board of Alpex Pharma S.A. and Teligent (NSDQ: TLGT, formerly IGI Laboratories), and also serves on the Board of Directors of Bionpharma Inc., Chr. Olesen Synthesis A/S, CoreRx Inc, and Spepharm AG. Prior portfolio company boards include Arbor Pharmaceuticals, Amarin Corporation, eResearch Technologies Inc., and Valera Pharmaceuticals.
Prior to founding Signet, Jim was head of principal investment activities and head of investment banking for Gruntal & Co., LLC. While at Gruntal, he made a number of investments including Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation, Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals).
Prior to joining Gruntal, he originated and managed private equity investments for the Home Insurance Co., Gruntal’s parent. Earlier in his career, Jim was a senior investment banker at E.F. Hutton & Co.
Jim received his Masters of Business Administration from the University of Chicago.
Ashley Friedman has over 15 years of healthcare investing and finance experience. Throughout his career, he has focused on the pharmaceutical and medical technology sectors.
Ashley joined Signet Healthcare Partners in 2014 and is currently a Managing Director in Signet Fund IV. Ashley focuses on pharmaceutical, medical device and diagnostic investments. Ashley currently serves on the Board of TelaBio.
Prior to joining Signet, Ashley spent over 11 years, most recently as a Vice President, working for Investor Growth Capital (Investor AB), a venture capital firm focusing on private and public healthcare investments. While at Investor Growth Capital, Ashley was involved with several successful investments in the biotechnology, specialty pharmaceutical and medical device sectors. Prior portfolio companies include Achillion Pharmaceuticals (NSDQ: ACHN), Cayenne Medical (acquired by Zimmer Biomet), CHF Solutions (acquired by Gambro), and Corcept Therapeutics (NSDQ: CORT). Ashley began his career at Lehman Brothers as a healthcare investment banker.
Ashley holds a Bachelor of Science from Yale University in both Economics and Molecular, Cellular & Developmental Biology (MCDB) with a concentration in biotechnology.
Nikhil Puri has over 20 years of experience serving the pharmaceutical industry. Nikhil has held senior positions within the pharma industry and as a healthcare investment banker.
Most recently prior to joining Signet as a Managing Director in Signet Fund IV, Nikhil was responsible for worldwide business development of the Global Established Pharmaceuticals ("GEP") business at Pfizer that encompasses a broad portfolio (annual revenues of c. $25 bn) of legacy brands, sterile injectables, generics and bio-similars. During his five-year tenure at Pfizer, a number of key inorganic growth initiatives were consummated for GEP including the acquisitions of Hospira, Innopharma and Nextwave Pharmaceuticals within the United States as well as several international transactions, including in Latin America, Japan and China. Nikhil was a member of both Pfizer's Business Development leadership team and the GEP leadership team and Investment Committee.
Prior to joining Pfizer, Nikhil spent 15 years as an investment banker in the United States and in Asia at firms including Lehman Brothers and Bear Stearns, predominantly focused on the pharmaceutical sector. During that time period he was involved in the consummation of over 50 capital raising and strategic advisory transactions with an aggregate value exceeding $20 bn for clients including Endo Pharmaceuticals, Valeant Pharmaceuticals and MedPointe.
Nikhil received his Masters of Business Administration from New York University. He has a bachelor's degree in commerce from the University of Mumbai and is a member of the Institute of Chartered Accountants of India.
PARTNERS & ADVISORS
Todd Sone has over fifteen years of healthcare and finance experience. Todd is a Venture Partner at Signet and has served on the Board of Arbor Pharmaceuticals and Apicore.
Prior to joining Signet, Todd was an Investment Director at Joddes Limited, an investment holding company with interests in a number of healthcare companies, including Pharmascience, Paladin Labs, Medicom, and Oral Science. He was the Director of Strategic Planning at Pharmascience Inc., one of the largest privately-owned generic pharmaceutical companies in the world.
Prior to joining Pharmascience, Todd was a large-cap pharmaceutical analyst at Morgan Stanley. He started his career at Mercer Management Consulting serving clients across North America in the transportation and healthcare industries.
Todd received a Bachelor of Commerce (with High Distinction) from the University of Toronto and an MBA from The Wharton School at the University of Pennsylvania.
David Tierney, MD is a Venture Partner with Signet Healthcare Partners. He serves as an advisor to Signet and also works closely with Signet portfolio companies. David currently serves as the CEO of Icon Bioscience.
Previously, David served as President & COO of Oceana Therapeutics, Inc., a specialty therapeutic company he co-founded in mid-2008. Oceana quickly established a global commercial network and by December 2011 was acquired by Salix Pharmaceuticals. In 2000, David was appointed President & CEO of Hydro Med Sciences (HMS), a research firm with a promising drug delivery platform. Under his leadership, HMS emerged as Valera Pharmaceuticals, a fully integrated, commercial, specialty pharma company that successfully completed an initial public offering in 2005. Valera has since been merged into Endo Pharmaceuticals. Prior to Valera, David was President of Biovail Technologies, a drug delivery division of Biovail Corporation – a predecessor to Valeant Pharmaceuticals International. Earlier in his career, he served as Senior VP, Drug Development at Roberts Pharmaceutical and in a variety of management positions at Elan Corporation.
David serves on the Board of Catalyst Pharmaceuticals, Inc (NSDQ: CPRX), Kempharm, Inc (NSDQ: KMPH) and Viatar CTC Solutions.
David received his medical degree from the Royal College of Surgeons in Dublin, Ireland.
Joyce Erony has more than 25 years of experience as a principal in investing activities, investment banking and business development. Joyce is a Partner Emeritus at Signet and serves as a Director of ImpoPharma, Icon Biosciences and Kew Group.
Joyce was previously a Director of IGI Labs, Peak Surgical (acquired by Medtronic), Dow Pharmaceutical Sciences (acquired by Valeant), Anteis (acquired by Merz), Atlantis Components (acquired by AstraZeneca), and Control Delivery Systems (acquired by Psivida).
Previously, Joyce was a strategic advisor to Alcon Labs and a Managing Director at Citigroup where she was focused on specialty pharmaceuticals and medical technologies.
Martin (Marty) Zeiger has more than 30 years of experience in the pharmaceutical industry, both branded and generic. Martin is an Adjunct Partner at Signet and is a Director of Sancilio & Company.
Prior to joining Signet Healthcare Partners, Martin was a Senior Vice President at Barr Laboratories, Inc. Prior to joining Barr, Martin was Executive Vice President and General Counsel at Rugby Laboratories (a privately held generic drug company) until its acquisition by Marion Merrill Dow, Inc. in 1993. He continued as a Vice President for Marion and its successor Company, Hoechst Marion Roussel, Inc.
Martin was honored by the Generic Pharmaceutical Industry Association at its March 2004 Annual Meeting as a generic industry founder. Prior to joining pharmaceutical manufacturing companies, Martin served as Vice President General Counsel for Jack Eckerd Corporation and Senior Vice President for Revco D.S. Inc., both major drug store retailers.
Martin received his LLB and JD from St. John’s University School of Law, where he served as Publications Editor of the Law Review. He is an attorney, admitted to practice in the State of New York.